1. Home
  2. FATE vs RANI Comparison

FATE vs RANI Comparison

Compare FATE & RANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Fate Therapeutics Inc.

FATE

Fate Therapeutics Inc.

HOLD

Current Price

$2.11

Market Cap

125.6M

Sector

Health Care

ML Signal

HOLD

Logo Rani Therapeutics Holdings Inc.

RANI

Rani Therapeutics Holdings Inc.

BUY

Current Price

$0.79

Market Cap

106.9M

Sector

Health Care

ML Signal

BUY

Company Overview

Basic Information
Metric
FATE
RANI
Founded
2007
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Medicinal Chemicals and Botanical Products
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
125.6M
106.9M
IPO Year
2013
2021

Fundamental Metrics

Financial Performance
Metric
FATE
RANI
Price
$2.11
$0.79
Analyst Decision
Buy
Strong Buy
Analyst Count
11
5
Target Price
$5.74
★ $7.20
AVG Volume (30 Days)
★ 1.6M
503.4K
Earning Date
11-12-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
29.88
★ 57.14
EPS
N/A
★ N/A
Revenue
★ $6,646,000.00
$1,633,000.00
Revenue This Year
N/A
$283.19
Revenue Next Year
N/A
$5.99
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 58.85
52 Week Low
$0.95
$0.45
52 Week High
$3.23
$3.87

Technical Indicators

Market Signals
Indicator
FATE
RANI
Relative Strength Index (RSI) 34.55 47.82
Support Level $1.81 $0.73
Resistance Level $2.62 $0.84
Average True Range (ATR) 0.15 0.05
MACD -0.03 0.00
Stochastic Oscillator 12.50 46.26

Price Performance

Historical Comparison
FATE
RANI

About FATE Fate Therapeutics Inc.

Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.

About RANI Rani Therapeutics Holdings Inc.

Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.

Share on Social Networks: